ACRV — ACRIVON THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About ACRIVON THERAPEUTICS INC (ACRV)
ACRIVON THERAPEUTICS INC (ACRV) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $4M. Across recent filings, tracked investors recorded 3 new positions, 1 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ACRV
How many top investors track ACRV
A small number of top investors own this.
ACRV Ownership Composition
How ACRIVON THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other99.4%
- Hedge Funds0.6%
Tracked investors reporting ACRV
- Ken GriffinDec 31, 2025Citadel AdvisorsShares1.6MValue$4M% Portfolio0.00%
- Izzy EnglanderDec 31, 2025Millennium ManagementShares121.5KValue$292.9K% Portfolio0.00%
- Steve CohenDec 31, 2025Point72 Asset ManagementShares10.9KValue$26.2K% Portfolio0.00%
Recent activity
- $292.9KFeb 17, 2026
- New$26.2KFeb 17, 2026
- Sold$0(-100.00%)May 15, 2026
- Increased$4M(6.52%)Feb 17, 2026
- New$2.8MNov 14, 2025
Frequently asked questions
- How many institutional investors hold ACRV?
- 3 tracked institutional investors disclosed a position in ACRV (ACRIVON THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of ACRV?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in ACRV, valued at $4M.
- Did institutional ownership of ACRV increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 1 increased, 0 reduced, and 1 fully exited ACRV.
- Where does this ACRV ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.